Recent Updates
Recently added Catalysts

DR-2011

Phase 3

Infertility | Small molecule | Other |Teva Pharmaceutical Industries Limited|Last Updated: May 12, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment1,317
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00615251A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro FertilizationPHASE3 COMPLETED 1,297Feb 1, 2008Aug 1, 2009Sep 13, 201329 United States
NCT00117468Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase ReplacementPHASE2 COMPLETED 20Jun 1, 2005Apr 1, 2006May 12, 20141 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Clinical pregnancy rate at 8 weeks and 12 weeks of pregnancy
8 weeks of pregnancy (6 weeks after egg retrieval) and 12 weeks of pregnancy (10 weeks after egg retrieval)
Adequate endometrial transformation
Cycle Day 25 or 26
Secondary Endpoints
Secondary outcome measures will include: live birth rate, cycle cancellation rate, rate of spontaneous abortion, rate of biochemical pregnancy, rate of ectopic pregnancy
Duration of study
Adverse events
Duration of study
Hormone levels
Duration of study
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTAL -
2ACTIVE_COMPARATOR -
Interventions
NameTypeDescription
DR-2011DRUGProgesterone vaginal ring for approximately 10 weeks
Crinone 8%DRUGprogesterone vaginal gel for approximately 10 weeks
Progesterone 8% Vaginal GelDRUGAdministered vaginally from Cycle Day 14 to Day 31
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 42 Years
SexFEMALE
Healthy VolunteersYes
Study Sites29

Inclusion Criteria: * Pre-menopausal, aged 18-42 old at time of consent * At least one cycle without fertility medication prior to screening * Tubal, idiopathic, male factor, ovulatory dysfunction or endometriosis- linked infertility * Semen analysis (frozen sperm, including donor sperm, may be use...

Countries:United States
Unlock Eligibility Criteria